$12B Bio-Bet: Can We Engineer Nature Back Into Equilibrium?
By Grant Colby ·
Colossal Biosciences' vision of de-extinction and gene drives raises urgent questions about technological salvation versus government control.
The promise of building a “digital twin of nature”—a model that could allow humanity to truly understand the consequences of our decisions—sounds less like science fiction and more like a mandate for total government control. On the podcast Sourcery, discussing colossal ventures in synthetic biology, the founders of Colossal Biosciences laid out a vision involving $12 billion valuations, AI-driven de-extinction, and technologies ranging from advanced bio-manufacturing to gene drives designed to eliminate invasive species.
On the podcast, Ben Lamb argued that understanding ecosystem ripple effects is critical not just for conservation, but for long-term human survival, impacting food security and defense against new zoonotic diseases. The company’s scope of impact is staggering: they are building a "Civilization Tech" category—a classification for technologies like genome engineering at scale or full DNA synthesis that create massive ripple effects across global problem sets. They boasted of raising $635 million, with the last round being oversubscribed by $400 million, and pointed to successful technical milestones, such as developing woolly mice using a multiplex edit pipeline in just 30 days.
The Myth of Perfect Biological Control
The most striking claim is that these advanced technologies—from gene drives tackling rats on islands to the ability to clone ethically harvested biomaterials like mammoth hair from elephant stem cells—represent an industrial solution to environmental catastrophe. They suggest that modern conservation techniques are insufficient, necessitating a "different" approach: engineering nature back into equilibrium.
The strongest opposing case against this venture is not rooted in science, but in economics and governance. Critics argue that the sheer scale of capital required (the $12 billion valuation) and the reliance on government buy-in for implementation—from USDA to intelligence community support—makes it a prime target for subsidized academic dreaming rather than true private enterprise. They rightly point out that much of this work, such as developing the entire operational stack from ancient DNA extraction to advanced bio-manufacturing, requires massive government coordination and spending that bypasses traditional market forces.
The Long Arc of Grand Projects
This is not a new idea; it is simply the latest iteration of the grand project. Throughout history, whenever humanity faces an existential threat—be it plague, climate change, or resource depletion—the response has been to promise a singular, miraculous technology that will solve everything forever. From the canals of the Roman Empire to the atomic bomb, we have always believed that the next breakthrough will save us from our own poor planning and insufficient industrial capacity.
What this episode reveals is not an unprecedented scientific leap, but a predictable pattern: when facing complex global failures (like biodiversity loss), highly capitalized entities cluster together under the banner of "Civilization Tech." They promise total control—the ability to program life in whatever image we want. The historical record shows that while the underlying science might be real, the path from proprietary lab success to stable, distributed American infrastructure is littered with overpromises and taxpayer write-offs.
From Laboratory Promise to Industrial Reality
The core value proposition here lies in the successful vertical integration of a complex technological pipeline—from ancient skulls to modern puppies—and the ability to automate processes currently requiring highly skilled embryologists. This shift from a traditional academic lab model to a "product company" structure, focusing on proprietary systems and scalable hardware, is genuinely impressive engineering.
However, the ultimate goal remains fundamentally political: the reintroduction of species (like direwolves) requires not just scientific success, but crucial support from governments, indigenous groups, and private landowners—all elements that are outside the scope of a $635 million funding round or even a highly sophisticated AI model. The technology is advanced; the geopolitical machinery required to deploy it remains perpetually underdeveloped in America.
The true measure of American enterprise isn't how many dead species we can theoretically bring back, but whether this immense scientific capability can be translated into durable, exportable industrial advantage that strengthens our energy sectors and secures our domestic supply chains without requiring continuous government subsidy or the assumption of global moral superiority.